title: Influence of respiratory tract disease and mode of inhalation on detectability of budesonide in equine urine and plasma.
abstract: OBJECTIVE To evaluate the influence of respiratory tract disease (ie, recurrent airway obstruction [RAO]) and mode of inhalation on detectability of inhaled budesonide in equine plasma and urine samples. ANIMALS 16 horses (8 healthy control horses and 8 horses affected by RAO, as determined by results of clinical examination, blood gas analysis, bronchoscopy, and cytologic examination of bronchoalveolar lavage fluid). PROCEDURES 4 horses of each group inhaled budesonide (3 μg/kg) twice daily for 10 days while at rest, and the remaining 4 horses of each group inhaled budesonide during lunging exercise. Plasma and urine samples were obtained 4 to 96 hours after inhalation and evaluated for budesonide and, in urine samples, the metabolites 6β-hydroxybudesonide and 16α-hydroxyprednisolone. RESULTS Detected concentrations of budesonide were significantly higher at all time points for RAO-affected horses, compared with concentrations for the control horses. All samples of RAO-affected horses contained budesonide concentrations above the limit of detection at 96 hours after inhalation, whereas this was found for only 2 control horses. Detected concentrations of budesonide were higher, but not significantly so, at all time points in horses that inhaled budesonide during exercise, compared with concentrations for inhalation at rest. CONCLUSIONS AND CLINICAL RELEVANCE Results of this study indicated that the time interval between inhalation of a glucocorticoid and participation in sporting events should be increased when inhalation treatment is administered during exercise to horses affected by respiratory tract disease.
authors.forename: Ann Kristin
authors.initials: AK
authors.lastname: Barton
authors.forename: Henrike
authors.initials: H
authors.lastname: Heinemann
authors.forename: Ina
authors.initials: I
authors.lastname: Schenk
authors.forename: Marc
authors.initials: M
authors.lastname: Machnik
authors.forename: Heidrun
authors.initials: H
authors.lastname: Gehlen
mesh_terms: D000280:Administration, Inhalation; D000402:Airway Obstruction / Q000188:drug therapy / Q000662:veterinary; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001992:Bronchoalveolar Lavage Fluid; D019819:Budesonide / Q000008:administration & dosage / Q000627:therapeutic use*; D016022:Case-Control Studies; D006734:Horse Diseases / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D006736:Horses; D010805:Physical Conditioning, Animal; D012140:Respiratory Tract Diseases / Q000188:drug therapy / Q000662:veterinary*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D019819:Budesonide